| Autor: |
Campos JL; Department of Microsurgery, Jesús Usón Minimally Invasive Surgery Centre, 10071 Cáceres, Spain., Pons G; Department of Plastic Surgery, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain., Al-Sakkaf AM; Department of Plastic Surgery, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain., Lusetti IL; Department of Plastic Surgery, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain., Pires L; Department of Microsurgery, Jesús Usón Minimally Invasive Surgery Centre, 10071 Cáceres, Spain., Vela FJ; Department of Microsurgery, Jesús Usón Minimally Invasive Surgery Centre, 10071 Cáceres, Spain., Ramos E; Department of Microsurgery, Jesús Usón Minimally Invasive Surgery Centre, 10071 Cáceres, Spain., Crisóstomo V; Jesús Usón Minimally Invasive Surgery Centre, 10071 Cáceres, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain., Sánchez-Margallo FM; Jesús Usón Minimally Invasive Surgery Centre, 10071 Cáceres, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain., Abellán E; Department of Microsurgery, Jesús Usón Minimally Invasive Surgery Centre, 10071 Cáceres, Spain., Masiá J; Department of Plastic Surgery, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain. |
| Abstrakt: |
Lymphedema presents significant challenges to patients' quality of life, prompting the exploration of innovative treatments, such as collagen scaffolds, aimed at treating and reducing the risk of lymphedema. We aimed to evaluate the preventive and therapeutic efficacy and the lymphangiogenic potential of implanted aligned nanofibrillar collagen scaffolds (BioBridge TM ) following the induction of secondary lymphedema in a rabbit model. Thirty rabbits were divided into treatment (G1), prevention (G2), and control (G3) groups. Secondary lymphedema was induced in all groups. BioBridge TM implantation was performed in G2 and G1 on days 0 and 60, respectively. Follow-ups included hindlimb circumference measurements and indocyanine green lymphography at 0, 60, and 90 days. None of the study rabbits exhibited dermal backflow on day 0 before surgery. At 60 days, the incidence rates of dermal backflow in G1, G2, and G3 were 100%, 44.4%, and 90%, respectively. Furthermore, at 90 days, the incidence rates were 22.2%, 44.4%, and 90%, respectively. New linear lymphatic observation was seen in rabbits with resolved dermal backflow. The findings of this study demonstrated the capacity of BioBridge TM scaffolds to induce new lymphatic vessel formation and reduce dermal backflow in secondary lymphedema in a rabbit model. |
